The recently released 2018 Medical Transportation Access Coalition (MTAC) about #NEMT cost savings to Medicaid and benefits to patients found more than $480 Million Annual ROI per 30,000 NEMT users. MTAC commissioned a first of its kind study to examine the return on investment of NEMT by examining actual Medicaid claims data and surveying actual NEMT users. The study was conducted by Faegre Baker Daniels Consulting, Wakely, and Dr. Patricia Salber.
Three conditions and corresponding treatments were evaluated: Dialysis for Kidney Disease, Wound Care for Diabetic Wounds, and Treatment for Substance Use Disorder (SUD).
The MTAC Study Results
The study supports the hypothesis that missed medical appointments lessens patient adherence with clinical guidelines, which leads to complications and expensive medical services. The value of NEMT is shown most clearly in the costs avoided from increased expensive medical services and lower treatment adherence for Dialysis for Kidney Disease and Wound Care for diabetic wounds, demonstrating that NEMT pays for itself as part of a care management strategy for people with certain chronic conditions.
REPORT: MTAC Medicare ROI Study
About MTAC
MTAC (https://mtaccoalition.org/) was formed in 2017 to educate federal and state policymakers about the benefits of non-emergency medical transportation (NEMT) and the need for policies that support continued access to transportation. Founded by the leading brokers of NEMT, LogistiCare Solutions, LLC, MTM, Inc., and Southeastrans, Inc., the coalition has quickly gained support and its current membership numbers 17 organizations including leading patient and health plan organizations.
